Open AccessPreoperative Anticoagulant Treatment in Gynaecological Surgery
Author(s) -
Pyörälä Tapani,
Lampinen Väinö
Publication year - 1970
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016347009157239
Subject(s) - medicine , warfarin sodium , anticoagulant drug , anticoagulant , anticoagulant therapy , surgery , pulmonary embolism , warfarin , thrombosis , myocardial infarction , atrial fibrillation
. The feasibility of preoperative anticoagulant treatment in connection with gynaecological surgery was studied in a series of 59 patients who were considered to have a predisposition to thromboembolic complications. The anticoagulant drug used was warfarin sodium (Marevan®) and Owren's Thrombotest (TT) method was employed in the control of the treatment. Clinically detectable venous thrombosis or pulmonary embolism did not occur in the series. In 1 case a non‐fatal myocardial infarction was diagnosed postoperatively. There were no deaths in the series. Clinically significant haemorrhagic complications occurred in 5 cases, but could be controlled in all instances. Our experience indicates that preoperative anticoagulant treatment is feasible in connection with gynaecological surgery. If the anticoagulant treatment is supervised carefully, it does not cause any undue increase in the risk of bleeding complications. However, careful haemostasis during surgery is imperative in patients receiving preoperative anticoagulant treatment. A TT level of 10–20% seems to be suitable in preoperative anticoagulant treatment.